Variant · Snv
FCGR2A H167R
CI-VAR-00001897Explore in graph →NP_001129691.1:p.His167ArgNM_001136219.1:c.500A>GClinVar 14823 CIViC 456 rs1801274
Curated evidence
Evidence by cancer (2 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24989892
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| HER2-Positive Breast Carcinoma1 | ||||||||
| FCGR2A H167R | Trastuzumab | Predictive | B | Does Not Support Sensitivity Response | 4 | accepted | EID10881325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistical difference in disease-free survival between tr… (full text at CIViC) PMID 24989892 · Norton et al., 2014 · Open in CIViC | civic |
| Malignant Breast Neoplasm1 | ||||||||
| FCGR2A H167R | (prognostic) | Prognostic | B | Does Not Support N/A | 3 | accepted | EID1084A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. FCGR2A H131R carriers did not have a significantly different response rate, pr… (full text at CIViC) PMID 22906996 · | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available